Eur J Pharmacol 553, 141-145, (2006). Brammer, M. K., Gilmore, D. L., & Matsumoto, R. R. View abstract in PubMed Post navigationPreviousPrevious post:Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia.NextNext post:Sigma receptor type 1 gene expression variation in a group of Polish patients with Alzheimer’s disease and mild cognitive impairment.Related PostsAnavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day®February 22, 2021Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook February 11, 2021Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021February 8, 2021Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s DiseaseJanuary 11, 2021
Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day®February 22, 2021
Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook February 11, 2021
Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021February 8, 2021
Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s DiseaseJanuary 11, 2021
